Mega-analysis of 400 THC infusions confirms THC induces psychosis-like symptoms in nearly half of healthy volunteers | Research

The takeaway

Pooling data from 10 studies with 400 intravenous THC infusions in healthy volunteers, clinically meaningful psychosis-like symptoms occurred in 45% of infusions, with effects increasing with dose and decreasing with frequent prior cannabis use.

Psychosis researchers, cannabis pharmacologists, and clinicians assessing THC-related psychiatric risk.

45% of THC infusions produced clinically meaningful psychosis-like symptoms

What the researchers found

44.75% of THC infusions produced clinically meaningful positive psychosis symptoms. Conceptual disorganization, hallucinations, blunted affect, and poor attention were most frequently affected. Higher THC doses increased symptoms, while frequent prior cannabis use blunted them.

Why it matters

This is the most comprehensive analysis of THC-induced psychosis-like effects in controlled settings, confirming the dose-dependent relationship and demonstrating that tolerance from regular use partially protects against these effects.

The numbers in context

400 IV THC infusions across 10 studies. 44.75% showed clinically meaningful positive symptom increases. Dose association: beta=11.13. Frequent cannabis use association: beta=-0.575. Strong correlation with perceptual alterations (rs=0.514).

How the study worked

Individual participant-data mega-analysis of 10 double-blind, randomized, placebo-controlled crossover studies using intravenous THC infusions in healthy volunteers. The PANSS (Positive and Negative Syndrome Scale) measured psychotomimetic effects.

What this study cannot tell us

Intravenous THC administration does not replicate real-world cannabis use (smoking, edibles). Participants were healthy volunteers, not people at high risk for psychosis. The controlled setting may moderate psychological responses.

How to read the evidence

Strong: individual participant-data mega-analysis of 10 controlled studies with 400 infusions.

When this study was published

Published in 2020 in International Journal of Neuropsychopharmacology.

The bigger picture

The finding that frequent cannabis users show blunted psychotomimetic responses suggests tolerance develops to these effects, which may partly explain why most regular users do not develop psychotic disorders despite repeated exposure to a psychotomimetic substance.

Questions still open

What distinguishes the 45% who had psychosis-like symptoms from the 55% who did not? Does the tolerance that blunts psychotomimetic effects also protect against long-term psychosis risk?

Common questions

Does THC cause psychosis in everyone?

No. Even in this controlled setting with intravenous THC (which produces stronger effects than smoking), only about 45% of infusions produced clinically meaningful psychosis-like symptoms. The effects were temporary and resolved after the drug wore off.

Why do regular cannabis users have weaker reactions?

Frequent cannabis use was associated with a blunted psychotomimetic response, likely reflecting tolerance. The brain adapts to regular THC exposure by adjusting cannabinoid receptor sensitivity, which dampens acute psychosis-like effects.

Read the original research

Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.

The international journal of neuropsychopharmacology, 23(9), 559-570

View on PubMed ↗Publisher’s paper ↗

Citation

Ganesh, Suhas; Cortes-Briones, Jose; Ranganathan, Mohini; Radhakrishnan, Rajiv; Skosnik, Patrick D; D'Souza, Deepak Cyril. (2020). Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.. The international journal of neuropsychopharmacology, 23(9), 559-570. https://doi.org/10.1093/ijnp/pyaa031